505 related articles for article (PubMed ID: 25539654)
1. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
Beeh KM; Watz H; Puente-Maestu L; de Teresa L; Jarreta D; Caracta C; Garcia Gil E; Magnussen H
BMC Pulm Med; 2014 Dec; 14():209. PubMed ID: 25539654
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
3. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
Santus P; Radovanovic D; Di Marco F; Raccanelli R; Valenti V; Centanni S
Pulm Pharmacol Ther; 2015 Dec; 35():42-9. PubMed ID: 26549785
[TBL] [Abstract][Full Text] [Related]
4. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
Watz H; Troosters T; Beeh KM; Garcia-Aymerich J; Paggiaro P; Molins E; Notari M; Zapata A; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2017; 12():2545-2558. PubMed ID: 28883722
[TBL] [Abstract][Full Text] [Related]
5. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
Beeh KM; Singh D; Di Scala L; Drollmann A
Int J Chron Obstruct Pulmon Dis; 2012; 7():503-13. PubMed ID: 22973092
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
Singh D; Jones PW; Bateman ED; Korn S; Serra C; Molins E; Caracta C; Gil EG; Leselbaum A
BMC Pulm Med; 2014 Nov; 14():178. PubMed ID: 25404569
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E
Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
[TBL] [Abstract][Full Text] [Related]
12. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
[TBL] [Abstract][Full Text] [Related]
13. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
[TBL] [Abstract][Full Text] [Related]
14. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease.
Jensen D; Alsuhail A; Viola R; Dudgeon DJ; Webb KA; O'Donnell DE
J Pain Symptom Manage; 2012 Apr; 43(4):706-19. PubMed ID: 22168961
[TBL] [Abstract][Full Text] [Related]
15. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
[TBL] [Abstract][Full Text] [Related]
16. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
[TBL] [Abstract][Full Text] [Related]
17. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Watz H; Mailänder C; Baier M; Kirsten A
BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
[TBL] [Abstract][Full Text] [Related]
18. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
19. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
